Part:BBa_K5063008:Design
TP1_P5 fusion protein coding sequence
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21COMPATIBLE WITH RFC[21]
- 23COMPATIBLE WITH RFC[23]
- 25COMPATIBLE WITH RFC[25]
- 1000COMPATIBLE WITH RFC[1000]
Design Notes
we aimed to avoid the coiling of the 2 proteins when we fused them, so a linker is added between them and ensure that the functions of the 2 proteins can still be performed after fusion.
Source
[1] Leong, D. P., Joseph, P. G., McKee, M., Anand, S. S., Teo, K. K., Schwalm, J. D., & Yusuf, S. (2017). Reducing the global burden of cardiovascular disease, part 2: prevention and treatment of cardiovascular disease. Circulation research, 121(6), 695-710.https://www.ahajournals.org/doi/epub/10.1161/CIRCRESAHA.117.311849 [2] Loo, S., Kam, A., Dutta, B., Zhang, X., Feng, N., Sze, S. K., ... & Tam, J. P. (2024). Broad-spectrum ginsentides are principal bioactives in unraveling the cure-all effects of ginseng. Acta Pharmaceutica Sinica B, 14(2), 653-666.https://www.sciencedirect.com/science/article/pii/S2211383523004227 [3] Dutta B, Loo S, Kam A, Sze SK, Tam JP. Ginsentide TP1 Protects Hypoxia-Induced Dysfunction and ER Stress-Linked Apoptosis. Cells. 2023 May 16;12(10):1401. doi: 10.3390/cells12101401. PMID: 37408235; PMCID: PMC10216702.
Lammi C, Fassi EMA, Li J, Bartolomei M, Benigno G, Roda G, Arnoldi A, Grazioso G. Computational Design and Biological Evaluation of Analogs of Lupin Peptide P5 Endowed with Dual PCSK9/HMG-CoAR Inhibiting Activity. Pharmaceutics. 2022 Mar 18;14(3):665. doi: 10.3390/pharmaceutics14030665. PMID: 35336039; PMCID: PMC8951016.